Community Health Systems vs DaVita
CYH and DVA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYH and DVA compare
DaVita is the larger company, worth 35 times as much as Community Health Systems ($12.0B against $338M).
On earnings, Community Health Systems is cheaper: it trades at 9.2× trailing earnings, against 13.8× for DaVita.
DaVita grew revenue faster over the last twelve months (6.4% versus −7.8% for Community Health Systems).
DaVita keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with 0.31% at Community Health Systems.
DaVita scores higher on the StockData Score (13 against 8 for Community Health Systems), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYH | DVA |
|---|---|---|
| Size and price | ||
| Market cap | $338M | $12.0B |
| Share price | $2.40 | $187.50 |
| Change, 1 year | −43.0% | 48.2% |
| Change, 5 years | −83.3% | 71.5% |
| Beta (5Y) | 1.69 | 0.39 |
| Employees | 57K | 78K |
| StockData Score | ||
| Total score | 8 | 13 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.2× (better) | 13.8× |
| P/S | 0.0× (better) | 0.8× |
| EV/EBITDA | 5.9× (better) | 8.0× |
| P/FCF | – | 9.2× |
| PEG | 0.08 (better) | 0.73 |
| FCF yield | −36.0% | 10.8% (better) |
| Fair value | – | $299.15 |
| Margin of safety | – | 37.3% |
| Growth | ||
| Revenue growth (TTM) | −7.8% | 6.4% (better) |
| Revenue growth, 5Y average | 1.2% | 3.4% (better) |
| Net income growth (TTM) | −89.1% | 19.2% (better) |
| EPS growth (TTM) | −89.3% | 39.9% (better) |
| EPS growth, 5Y average | −3.0% | 9.3% (better) |
| Profitability | ||
| Gross margin | 85.5% | – |
| Operating margin | 10.9% | 15.0% (better) |
| Net margin | 0.31% | 6.5% (better) |
| FCF margin | −1.0% | 9.1% (better) |
| Return on invested capital | 7.5% | 18.1% (better) |
| Financial health | ||
| Net debt / EBITDA | 5.54 | 3.63 (better) |
| Current ratio | 1.48 (better) | 1.41 |
| Altman Z-score | 1.00 | 1.72 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 6.1% |
| Shareholder yield | 0.00% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 92.5% |
| Held by insiders | 9.0% | 58.4% |
| Insider net buying, 12 months | −$118K (better) | −$454M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.6% | 19.4% |
Go deeper
- CYH stock overview
- CYH income statement
- CYH valuation and score
- DVA stock overview
- DVA income statement
- DVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.